Detalhe da pesquisa
1.
Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.
J Urol
; 211(4): 564-574, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38153961
2.
Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
Mod Pathol
; 36(11): 100300, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37558130
3.
Triple extraction method enables high quality mass spectrometry-based proteomics and phospho-proteomics for eventual multi-omics integration studies.
Proteomics
; 21(16): e2000303, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34240547
4.
TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
Br J Cancer
; 120(5): 555-564, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30765874
5.
IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.
BMC Cancer
; 17(1): 636, 2017 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882129
6.
Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer.
Hum Mol Genet
; 23(20): 5545-57, 2014 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24861552
7.
Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma.
Pediatr Blood Cancer
; 61(2): 383-6, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24115570
8.
Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
Eur Urol
; 85(5): 483-494, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37380559
9.
A new tumorgraft panel to accelerate precision medicine in prostate cancer.
Front Oncol
; 13: 1130048, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37305585
10.
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Cancers (Basel)
; 15(6)2023 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36980628
11.
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks.
Oncogene
; 42(19): 1524-1542, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36944729
12.
FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Eur Urol
; 83(1): 70-81, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273937
13.
Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
Front Oncol
; 12: 930731, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36033544
14.
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.
Oncoimmunology
; 8(5): e1581556, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31069145
15.
Recurrent activating mutations of PPARγ associated with luminal bladder tumors.
Nat Commun
; 10(1): 253, 2019 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30651555
16.
An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.
EMBO Mol Med
; 10(4)2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29463565
17.
Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.
Cell Rep
; 9(4): 1235-45, 2014 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25456126
18.
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.
Sci Transl Med
; 6(244): 244ra91, 2014 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25009231